Structure Therapeutics (GPCR) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed MannKind (MNKD) over the past year, losing 9.8% versus a loss of 37.1%. Structure Therapeutics is the larger company by market cap ($1.83 billion vs $1.10 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | MNKD |
|---|---|---|
| Share price | $25.67 | $3.42 |
| Market cap | $1.83B | $1.10B |
| 1-day change | -3.79% | -0.87% |
| YTD return | -63.09% | -39.68% |
| 1-year return | -9.77% | -37.13% |
| 5-year return | — | -32.81% |
| Forward P/E | — | 26.82 |
| EPS (TTM) | $-3.03 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-141.20M | — |
| 52-week high | $94.90 | $6.51 |
| 52-week low | $25.09 | $2.23 |
| Distance from 52-week high | -72.95% | -47.47% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +312.08% | +129.24% |
| Average volume | 965.00K | 4.50M |
| Shares outstanding | 71.31M | 321.54M |
| Employees | 281 | 591 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed MNKD by 27.4 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
GPCR vs MNKD FAQ
Which is bigger, Structure Therapeutics or MannKind?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.83B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, GPCR or MNKD?
GPCR returned -9.77% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and MannKind in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.